AMBLER, PA -- (MARKET WIRE) -- June 01, 2006 -- QuantRx® BioMedical Corporation (OTCBB: QTXB) announced that its shares of common stock are now being quoted on the OTC Bulletin Board.

Mr. Walter Witoshkin, President and Chief Executive Officer of QuantRx® states, "The move to the OTC BB is part of our steady financial and market growth strategy for QuantRx®. We anticipate that the broader capital market acceptance on the OTC BB will provide QuantRx® increased access to the investment community. The move to the OTC BB represents a significant financial milestone for QuantRx®, and is consistent with our plans of creating value for our shareholders through expansion of end user markets. Moving to OTC BB is the first of many steps QuantRx® is taking to expand its market presence, not only in the capital markets, but in the end user/customer markets."

About QuantRx® BioMedical Corporation

QuantRx® BioMedical Corporation (OTCBB: QTXB) is a bio-medical company that seeks to develop, acquire, and commercialize on its own or with other commercial partners proprietary medical technology and products for diagnostics and treatment of medical needs.

This press release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. QuantRx® has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential," and similar expressions. These statements reflect QuantRx's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause QuantRx's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. There can be no assurance that such factors will not affect the accuracy of such forward-looking statements. QuantRx® undertakes no obligation to update or advise in the event of any change, addition or alteration to the information set forth in this press release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of any offer to buy; nor will there be any sale of securities of QuantRx® BioMedical Corporation in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states.